Client genetics and analysis agency 23andMe mentioned on Friday that it has signed an settlement to amass Lemonaid Well being, which presents on-line entry to quite a lot of telemedicine and pharmacy providers, for $400 million in money and inventory.
Beneath the phrases of the deal, 23andMe will purchase San Francisco-based Lemonaid for $100 million in money and $300 million in widespread inventory. The transaction is anticipated to shut by the top of the yr.
“We consider that by combining Lemonaid Well being’s telemedicine platform, together with its on-line group of medical professionals and its pharmacy providers, with our client enterprise, we’re taking an essential step in remodeling the normal major care expertise and making customized healthcare a actuality,” 23andMe cofounder and CEO Anne Wojcicki mentioned in an announcement. “By beginning with genetics as the inspiration, we are going to give sufferers and healthcare suppliers higher details about well being dangers and coverings, opening up the door to stop in addition to higher handle illness.”
In August, newly public Sunnyvale, California-based 23andMe reported a 23 % enhance in first quarter revenues on sturdy gross sales of its Private Genome Service equipment, which makes use of genotyping to detect clinically related variants in genomic DNA from saliva samples.
